Well, I do think the PEARL trial is useful in one respect, and that is safety at the dosages used. The high dose in men translated to coated version amounted to 3mg/week, at which point there were no real adverse effects, and mere hints at positive effects, at least directionally. But let us not forget that women on the higher dose did experience some minor benefits - whether that’s sex related or dose/body weight related we don’t know.
I therefore concluded that (for me) a starting dose of 3mg/week makes sense (based on the PEARL “do no harm” protocol), and then experimentally escalate, measuring rapa blood levels, but also importantly biomarkers and set criteria. To this end I have generated a table wherein I’ve been recording various effects prior to taking rapa, in the last 3 months or so, such like gum health (which I asked my periodontist to make an extensive and very exacting measurement and documentation to establish a baseline), I have a dermatology exam coming up, and I’ll get the same baseline record, augmented by my wife photographing my whole body skin, performing a gray hair count on my head, carefully monitoring, measuring (trackers) exercise performance and recovery effects, various aches, rashes, pimples, intestinal effects (random stomach cramps etc.), bathroom frequency and so on. Why? Because it is easy to forget that yes, I would get a pimple sometimes, or have this level of soreness, DOMS after exercise, these occasional gastrointestinal effects, and ascribe them later to rapa, good or bad. You have to have an exacting baseline to make reasonable comparisons and judge dose effects as you escalate. Have a record prior to the intervention so you have grounds for comparison.
Also, I believe dosages must be optimised for individuals. Mice in a given cohort don’t have, seems to me, as drastic individual body size differences as humans, and so you could use a single dose amount for all. But f.ex. dogs differ dramatically in size, so giving the same dose to a mastiff and a pug would be absurd. Hence, for dogs (and cats) they standardize per body weight (which the don’t bother for mice), I believe it was something like 0.15 per kg. I believe the same must happen for humans. I find it absurd when studies just use one dose for all - and perhaps that might account for some of the sex differences in human reaction to rapa. In humans, size matters 
Start (s)low, but not too low (see the posts where an mtorc researcher claimed a too low dose actually activates mtorc1), and escalate from there, slowly, while carefully monitoring and measuring effects against a baseline.
For me, I’ll start with 3mg/week for 4 weeks, and go up 1mg every 4 weeks till I hit 6mg/week, stay there for a few months to see if there are any longer term effects that emerge, and then move up slowly to 8-10mg/week and see what that does for me. Right now I’m waiting for the rapa to arrive from India (with empa, pita, telmi), stuck at customs. But I won’t start until all my baseline measurements have been completed, blood panels, DEXA, CIMT etc. Then I’ll first do all my initial interventions, change statin, stabilize blood glucose, blood pressure, gets the rest of my vaccinations. And then finally it’s off to the races, and measure, measure, measure. That’s my plan, FWIW - critiques and feedback welcome!
